Dales Pharmaceuticals is moving its business applications onto Oracle E-Business Suite to support growth plans in the US.
The company, which specialises in contract manufacturing of pharmaceuticals, selected Oracle E-Business Suite to standardise and automate business processes such as invoicing and improve product planning.
By submitting your email address, you agree to receive emails regarding relevant topic offers from TechTarget and its partners. You can withdraw your consent at any time. Contact TechTarget at 275 Grove Street, Newton, MA.
As well as creating internal efficiencies by rationalising three legacy systems, the move to Oracle will help Dales Pharmaceuticals manage its expansion into Europe, the US and Japan.
In particular, it should help it comply with the rigorous regulatory requirements of the US Food and Drug Administration (FDA). Mike Annice, managing director of Dales Pharmaceuticals, said the firm could comply with FDA regulations with its current paper-based system, but that would become untenable given the company's plans for 75% growth over the next five years.
"Oracle will allow us to continue to comply with regulatory authorities around the world without taking on huge numbers of employees. It is a project about future cost avoidance as well as immediate efficiencies," he said.
Dales Pharmaceuticals is rolling out Oracle E-Business Suite and Oracle Database 10g on Red Hat Linux to replace a Sage finance system, bespoke AS/400 business management application and paper-based compliance system.
The system will run on two Dell/Intel servers, which replicate to two identical servers at a separate site for business continuity. It is being deployed by Oracle reseller Mi Services.
Dales Pharmaceuticals opted for Oracle after an evaluation of four other products. "The system looks like it has been written for the regulatory requirements for our industry, whereas the others look like products for the manufacturing industry with add-ons for our industry," said Annice.
Kirsty Ireland, finance director at Dales Pharmaceuticals, said the system was just entering the user acceptance phase and would go live with Oracle Manufacturing and Financials around July. "We saw the whole project as an opportunity to look at our business processes and consider which we needed to change," she said.